2022年6月15日 · M1231 is a bispecific antibody-drug conjugate (ADC) based on a SEED (strand-exchange engineered domain)-antibody scaffold targeting tumor-associated MUC1 and EGFR. Sutro Biopharma’s cell free expression system Xpress CF+™ enables incorporation of non-natural amino acids at precise positions in the SEED-antibody for site-specific linker ...

4/Sutro+默克：M1231“非天然氨基酸、体外蛋白合成系统” 助力M1231光明前景 M1231是靶向MUCI/EGFR的双抗ADC。2021年该药已经进入临床。

M1231是Sutro和默克子公司EMD Serono合作开发的MUC1/EGFR双抗ADC，采用非天然氨基酸定点偶联技术，通过可裂解VC连接子偶联hemiasterlin衍生物（微管抑制剂），DAR为4。

2021年5月24日 · 由Sutro Biopharma和EMD Serono共同开发的M1231是一款靶向EGFR和MUC1的双特异性抗体ADC。 M1231是利用Sutro公司特有的XpressCF+技术开发的First-in-class创新药。 M1231拥有专有的SEED（Strand-Exchange Engineered Domain）不对称重链抗体结构，通过可切割的Val-Cit SUTRO链接子与特有的 ...

Results: M1231 potently inhibited cell viability of EGFR mutant and TKI resistant NSCLC cell lines with subnanomolar to single digit nanomolar IC 50 values. According to DNA content analysis and western blotting, M1231 treatment led to an arrest at G2/M phase that was accompanied by an increase in phospho-histone H3 levels.

2021年12月3日 · 创新双特异性抗体偶联药物治疗多种癌症. M1231是一款同时靶向MUC1和EGFR的抗体偶联药物（ADC） 。 MUC1和EGFR同时在很多实体瘤中表达，但是它们在正常组织中表达的水平很低。 同时靶向MUC1和EGFR提高了M1231对肿瘤的特异性，并且降低了潜在毒副作用。 MUC1和EGFR在多种实体瘤中同时表达（图片来源：参考资料 [1]） 而且， M1231与细胞上的MUC1和EGFR同时结合会促进ADC被细胞内吞，提高载荷的效力。 它在非小细胞肺癌和 …

2021年6月1日 · M1231 is a first-in-class investigational bispecific ADC; by targeting both MUC1 and EGFR, M1231 could potentially increase tumor selectivity, payload delivery, and reduce on-target toxicity on normal tissues.”

2023年1月1日 · A bispecific anti-mucin 1-epidermal growth factor receptor ADC (MUC1/EGFR bispecific ADC), M1231, has been evaluated for the first time in humans in a phase 1 study for the treatment of advanced solid tumors, especially metastatic non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma, which have a high MUC1/EGFR co ...

anti-MUC1/EGFR bispecific antibody-drug conjugate M1231 An antibody drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) mucin-1 (MUC1) and human epidermal growth factor receptor (EGFR), conjugated, via a cleavable valine-citruline-based linker, to the hemiasterlin-related toxic warhead ...

2022年6月15日 · M1231 inhibited tumor cell viability in vitro at sub-nanomolar IC50 values. The bispecific MUC1xEGFR antibody has demonstrated superior internalization and lysosomal trafficking compared to...